164 related articles for article (PubMed ID: 15891505)
1. Fluorodeoxyglucose positron emission tomography pattern of pulmonary lymphangitic carcinomatosis.
Digumarthy SR; Fischman AJ; Kwek BH; Aquino SL
J Comput Assist Tomogr; 2005; 29(3):346-9. PubMed ID: 15891505
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT in assessment of pulmonary lymphangitic carcinomatosis.
Prakash P; Kalra MK; Sharma A; Shepard JA; Digumarthy SR
AJR Am J Roentgenol; 2010 Jan; 194(1):231-6. PubMed ID: 20028927
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Lymphangitic Carcinomatosis: Diagnostic Performance of High-Resolution CT and
Jreige M; Dunet V; Letovanec I; Prior JO; Meuli RA; Beigelman-Aubry C; Schaefer N
J Nucl Med; 2020 Jan; 61(1):26-32. PubMed ID: 31227574
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary lymphangitic carcinomatosis (PLC): spectrum of FDG-PET findings.
Acikgoz G; Kim SM; Houseni M; Cermik TF; Intenzo CM; Alavi A
Clin Nucl Med; 2006 Nov; 31(11):673-8. PubMed ID: 17053382
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
6. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
[TBL] [Abstract][Full Text] [Related]
7. Complete Metabolic Response in Adenocarcinoma Lung With Lymphangitic Carcinomatosis.
Goyal H; Kishore S; Ganesan P; Halanaik D
Clin Nucl Med; 2023 Mar; 48(3):e133-e134. PubMed ID: 36252925
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.
Gupta N; Gill H; Graeber G; Bishop H; Hurst J; Stephens T
Chest; 1998 Oct; 114(4):1105-11. PubMed ID: 9792584
[TBL] [Abstract][Full Text] [Related]
10. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
[TBL] [Abstract][Full Text] [Related]
11. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
12. Differentiation of tumor recurrence from radiation-induced pulmonary fibrosis after stereotactic ablative radiotherapy for lung cancer: characterization of 18F-FDG PET/CT findings.
Nakajima N; Sugawara Y; Kataoka M; Hamamoto Y; Ochi T; Sakai S; Takahashi T; Kajihara M; Teramoto N; Yamashita M; Mochizuki T
Ann Nucl Med; 2013 Apr; 27(3):261-70. PubMed ID: 23299492
[TBL] [Abstract][Full Text] [Related]
13. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
[TBL] [Abstract][Full Text] [Related]
14. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study.
Hara T; Kosaka N; Suzuki T; Kudo K; Niino H
Chest; 2003 Sep; 124(3):893-901. PubMed ID: 12970014
[TBL] [Abstract][Full Text] [Related]
15. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
[TBL] [Abstract][Full Text] [Related]
16. F-18 FDG PET scan findings in patients with Loeffler's syndrome.
Chung SY; Lee JH; Kim TH; Yun M; Kim TS; Kim SJ; Kim HJ; Pai M; Lee JD; Ryu YH
Clin Nucl Med; 2009 Sep; 34(9):570-5. PubMed ID: 19692816
[TBL] [Abstract][Full Text] [Related]
17. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake value differences between primary and metastatic lesions in ¹⁸F-FDG PET/CT of patients with lung cancer.
Kosaka N; Tsuchida T; Tsuji K; Shimizu K; Kimura H
Acta Radiol; 2015 Nov; 56(11):1329-35. PubMed ID: 25398775
[TBL] [Abstract][Full Text] [Related]
19. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
[TBL] [Abstract][Full Text] [Related]
20. Lipomatous hypertrophy of the interatrial septum: prevalence and features on fusion 18F fluorodeoxyglucose positron emission tomography/CT.
Kuester LB; Fischman AJ; Fan CM; Halpern EF; Aquino SL
Chest; 2005 Dec; 128(6):3888-93. PubMed ID: 16354859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
